权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

2016 New Antibacterial Discovery and Development Gordon Research Conference and Gordon Research Seminar

2016新型抗菌药物发现与开发戈登研究大会暨戈登研究研讨会

基本信息

批准号：
9023674
负责人：
Jennifer Alyson Leeds
金额：
$ 0.7万
依托单位：
GORDON RESEARCH CONFERENCES
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-02-15 至 2017-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9023674
关键词：
Academia Address Adjuvant Anti-Bacterial Agents Antibiotic Resistance Antibiotics Area Basic Science Biotechnology Charge Chemicals Clinic Clinical Clinical Data Clinical Pathways Clinical Trials Clinical Trials Design Collaborations Communities Community Networks Companions Critical Thinking Critiques Data Data Analyses Development Diagnosis Diagnostic Drug Industry Drug resistance Educational workshop Environment Europe Experimental Designs Fostering Foundations Generations Goals Government Government Agencies Human Industry Infection Leadership Learning Medicine Microbial Physiology Organism Organizational Change Outcome Participant Patients Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacology Preclinical Testing Program Development Research Research Personnel Risk-Taking Safety Scientist Site Talents Time Translational Research Validation base career design drug development drug discovery experience innovation interest meetings new technology next generation novel novel strategies posters programs public health relevance research facility success support network symposium

项目摘要

DESCRIPTION (provided by the applicant): The 2016 Gordon Research Conference on New Antibacterial Discovery and Development and the companion Gordon Research Seminar will bring highly experienced leaders in antibacterial drug discovery and development together with young investigators and those new to the field of antibiotics research in order to enable the next generation of safe and effective drugs. Discussion leaders and speakers are chosen from academia, industry, and government agencies to emphasize the breadth of talent and leadership necessary to drive innovation around target discovery and validation, hit identification and chemical optimization, and clinical trial design and execution. Previous meetings have defined the problem of antibiotic resistance, the challenges in antibiotic discovery and development faced over the past two decades, and the need for new pathways for clinical development. Those meetings have successfully created a community of idea generation and collaboration in what is otherwise a highly competitive scientific arena. This meeting will build o those foundations by exploring 1) novel strategies for achieving potent and safe antibacterial drugs against the most difficult-to- treat organisms, 2) new approaches for diagnosing infections with the goal of broadening the opportunities for clinical development as well as guiding the appropriate use of precious new antibacterial drugs in the clinic, and 3) learnings from recent clinical programs with new and established targets which may be translatable to the next generation of antibacterial drugs. Many strategic and organizational changes have taken place in the biotech and pharmaceutical industry over the last few years as well as a shift in emphasis at academic and government research facilities from early basic science to translational research. Because of the ever-changing environment, there has never been a more critical time for fostering a community of intellectuals dedicated to innovation and calculated risk-taking. This GRC/GRS will enable critical thinking, robust discussions around data gathering and interpretation, and learning from each other's challenges and successes. Most importantly the GRC/GRS meeting will provide a community and support network for scientists who have dedicated their careers to one of the most difficult and essential areas of human medicine.

描述（由申请人提供）：2016 年戈登新抗菌药发现和开发研究会议及其配套的戈登研究研讨会将汇集抗菌药物发现和开发方面经验丰富的领导者以及年轻的研究人员和抗生素研究领域的新手，以实现下一代安全有效的药物。讨论领袖和演讲者是从学术界、工业界和政府机构中选出的，以强调围绕目标发现和验证、命中识别推动创新所需的人才和领导力的广度化学优化以及临床试验设计和执行。之前的会议明确了抗生素耐药性问题、过去二十年抗生素发现和开发面临的挑战以及临床开发新途径的需求。这些会议成功地在竞争激烈的科学领域创建了一个创意产生和协作的社区。本次会议将通过探索以下内容奠定这些基础：1）针对最难治疗的生物体开发出有效且安全的抗菌药物的新策略；2）诊断感染的新方法，旨在扩大临床开发机会并指导在临床中正确使用宝贵的新型抗菌药物；3）从最近的临床项目中获得的经验教训，这些项目具有新的和既定的目标，这些目标可以转化为下一代药物抗菌药物。过去几年，生物技术和制药行业发生了许多战略和组织变革，学术和政府研究机构的重点也从早期基础科学转向转化研究。由于环境不断变化，现在是培养致力于创新和有计划地承担风险的知识分子群体的关键时刻。这 GRC/GRS 将促进批判性思维、围绕数据收集和解释的激烈讨论，以及从彼此的挑战和成功中学习。最重要的是，GRC/GRS 会议将为那些致力于人类医学最困难和最重要领域之一的科学家提供一个社区和支持网络。